longevityGraveyard archive2016–2020

resTORbio

resTORbio was one of the first well-funded public attempts to drug aging itself — and one of the first to show how brutal the geroscience gauntlet would be. Founded in 2016 by Chen Schor and Joan Mannick and spun out of Novartis, it in-licensed the pharma giant's TORC1 program, including lead compound RTB101, on the thesis that selectively inhibiting the mTOR pathway could rejuvenate aging immune systems and cut the burden of age-related disease in older adults. The story had everything the field wanted: real Novartis science, a mechanism with rapamycin's pedigree behind it, and a January 2018 Nasdaq IPO (ticker TORC) that raised roughly $89 million on top of about $65 million in private capital. Then the science met a Phase 3 endpoint.

Years active

2016–2020

Total raised

$154M

Peak headcount

50

Spinning aging out of Novartis

resTORbio began inside big pharma. Joan Mannick, working at the Novartis Institutes for BioMedical Research, had run some of the most talked-about human data in geroscience — trials suggesting that low-dose TORC1 inhibitors could improve elderly patients' response to influenza vaccine, a tantalizing hint that you could measurably rejuvenate an aging immune system. In 2016 Mannick and biotech operator Chen Schor spun that work out into resTORbio, in-licensing worldwide rights to Novartis's TORC1 program — including the lead compound that became RTB101 — with Novartis retaining a minority stake. It was one of the purest 'treat aging as the disease' bets ever taken into a company.

The mTOR thesis, well capitalized

The geroscience pitch was compelling: the mTOR pathway is one of the most conserved regulators of aging across species, rapamycin extends lifespan in mice, and RTB101 was a selective oral TORC1 inhibitor that might deliver the benefits with a cleaner profile. Investors bought it. resTORbio raised roughly $65 million privately — anchored by a $40 million Series B led by OrbiMed in late 2017 — then IPO'd on Nasdaq in January 2018 under the ticker TORC, netting about $89 million more. That put well over $150 million behind a single, unusually ambitious idea: not treating one disease of aging, but the aging of the immune system that lets many diseases in.

Betting the company on respiratory infection

resTORbio chose to prove the thesis in respiratory illness in the elderly — a large, measurable indication where an aging immune system's failures show up as pneumonia, bronchitis, and hospitalizations. RTB101 advanced into the Phase 3 PROTECTOR 1 trial, testing whether the drug could reduce clinically symptomatic respiratory illness in adults 65 and older. The company also ran an early Parkinson's program, but PROTECTOR 1 was the catalyst that mattered: a clean win would have been the first pivotal validation that inhibiting an aging pathway could keep older people out of the clinic. The entire equity story rode on it.

November 2019: the endpoint that didn't hold

On November 15, 2019, resTORbio announced that PROTECTOR 1 had failed to meet its primary endpoint — RTB101 did not significantly reduce the percentage of patients with clinically symptomatic respiratory illness. The stock cratered, and the company halted the respiratory program. It was a textbook geroscience heartbreak: promising mid-stage immune-function signals that did not translate into a hard clinical outcome at pivotal scale. There was no safety scandal and no fraud — just the ordinary, unforgiving arithmetic of a Phase 3 miss in a field where the biology is real but the translational path is treacherous, and where a single trial can erase a company's entire reason to exist.

Reverse-merged into oncology

With its lead program dead and a cash-rich but purposeless shell, resTORbio did what failed biotechs with clean balance sheets do: it became a landing pad. In 2020 it reverse-merged with Adicet Bio, a private developer of off-the-shelf allogeneic gamma-delta CAR-T cell therapies for cancer. At closing the company executed a reverse stock split, took the name Adicet Bio, Inc., kept a Nasdaq listing, and pivoted entirely to oncology — the mTOR aging pipeline was abandoned outright. resTORbio's real legacy was cautionary and clarifying: it was among the first companies to take the geroscience hypothesis all the way to Phase 3, and its failure taught the field how much harder proving 'treat aging' would be than the mouse data and the vaccine-response signals had made it look.

What worked, what broke

What worked

Was one of the first companies to take the geroscience thesis — that inhibiting the mTOR/TORC1 aging pathway could treat age-related disease — into a well-funded, clinical-stage public company.
Spun directly out of Novartis, in-licensing the TORC1 program and lead compound RTB101 and carrying the credibility of Joan Mannick's widely cited elderly-immune-function human data.
Raised roughly $65 million privately, including a $40 million Series B led by OrbiMed, then IPO'd on Nasdaq in January 2018 (ticker TORC) for about $89 million more.
Advanced RTB101 into a genuine Phase 3 pivotal trial (PROTECTOR 1) in respiratory illness in older adults — a rare instance of an aging-pathway drug reaching late-stage testing.
Left the cleaner balance sheet and public listing that enabled Adicet Bio to go public and advance its allogeneic gamma-delta CAR-T oncology platform.

What broke

The pivotal Phase 3 PROTECTOR 1 trial of RTB101 missed its primary endpoint in November 2019, failing to significantly reduce clinically symptomatic respiratory illness in adults 65 and older.
The company had concentrated its equity story on a single lead asset in a single indication, so the Phase 3 miss removed its entire near-term reason to exist.
Promising mid-stage immune-function and vaccine-response signals did not translate into a hard clinical outcome at pivotal scale — the recurring translational trap of geroscience.
With the respiratory program halted and no other late-stage catalyst, resTORbio was left a cash shell whose most valuable feature was its Nasdaq listing.
The 2020 reverse merger into Adicet Bio pivoted the combined company entirely to gamma-delta CAR-T oncology and abandoned resTORbio's aging pipeline, ending it as a geroscience company.

Sources

Obituary authored Jul 2, 2026 via Sonnet 4.5 + web_search.

What’s new

Join affiliate network